Pneumonia in Pakistan: the national guideline offers two options, one has expired

The Pakistan Chest Society guideline gives you two options for a previously healthy outpatient with community-acquired pneumonia: amoxicillin, or a macrolide.

One of those has expired. The guideline is not wrong — it simply predates the resistance data, and reading it against current numbers tells you which half to take.

The macrolide problem, in the guideline's own terms

IDSA 2019 recommends macrolides for CAP only where local pneumococcal resistance is below 25%. That is a conditional recommendation with a stated precondition.

Pakistani Streptococcus pneumoniae macrolide susceptibility was 33% in 2015–17 — resistance of roughly two thirds.

So azithromycin monotherapy is not an empiric option for CAP in Pakistan, and you do not need a Pakistani guideline to tell you that. The international guideline tells you, by its own criterion.

What did hold up

For Haemophilus influenzae over the same period: co-amoxiclav 100%, levofloxacin 77.1%, moxifloxacin 75.4%, co-trimoxazole 41%.

So the guideline's other first-line option — amoxicillin — is intact. Take that one.

The line that gets misread

Penicillin sits at 23.4% susceptible in the same dataset where amoxicillin is "high, maintained". Reading those two lines together is the commonest misinterpretation of a pneumococcal sensitivity report, and it leads people to abandon a drug that still works.

The gap is a breakpoint artefact. CLSI applies stricter thresholds to oral penicillin than to amoxicillin at adequate dose in non-meningeal infection. Different drug, different breakpoint, same organism. Do not discard amoxicillin because the penicillin line looks bad.

The fluoroquinolone problem is not microbiological

Respiratory fluoroquinolones work well enough against these organisms — 75–77% against H. influenzae. The guideline offers levofloxacin or moxifloxacin as an option for outpatients with comorbidity, and as an alternative in inpatients.

The reason to hesitate in Pakistan has nothing to do with pneumococcus. Fluoroquinolones have antimycobacterial activity, and Pakistan carries one of the world's highest tuberculosis burdens. An empiric respiratory fluoroquinolone in a patient whose "pneumonia" is actually TB will partially treat it — blunting the clinical picture, delaying the diagnosis, and selecting for fluoroquinolone-resistant TB.

No international CAP guideline carries that caveat, because they are written for settings where TB is rare. Here it is a reason to prefer a β-lactam backbone unless there is a specific reason not to.

Subacute onset, weight loss, night sweats, haemoptysis, upper-lobe or cavitating changes, or failure to respond to an appropriate antibiotic should all prompt sputum testing for TB rather than a second course of antibiotics.

Before any of that: is it pneumonia?

The guideline is explicit that "a demonstrable infiltrate by chest radiograph or other imaging technique, with or without supporting microbiological data, is required for the diagnosis of pneumonia."

A febrile cough with crackles and a clear film is not pneumonia. Treating it as such accounts for a large share of the avoidable antibiotic use behind those susceptibility figures.

Severity: where the patient goes

CURB-65 — confusion, urea, respiratory rate, blood pressure, age 65 or over — to identify candidates for outpatient treatment. The guideline adds a caveat worth quoting, because it matters more here: the score "must be influenced by other factors such as compliance and reliability of taking oral medication as well as the availability of family support." Where a patient may not return, that judgement outweighs the number.

Direct ICU admission for either major criterion — invasive mechanical ventilation, or septic shock needing vasopressors. Three or more minor criteria mean ICU or a high-level monitoring unit: respiratory rate above 30, PaO₂/FiO₂ below 250, multilobar infiltrates, confusion, urea above 20 mg/dL, white cells below 4,000, platelets below 100,000, temperature below 36 °C, or hypotension requiring aggressive fluid resuscitation.

The guideline notes that patients transferred to ICU within the first 24–48 hours do worse than those admitted directly — which is the argument for scoring properly on arrival rather than waiting to see.

Three things about antibiotics here that no guideline accounts for

Antibiotics are sold without prescription. The Drug Act of 1967 prohibits it, but enforcement is inadequate and most classes are obtainable on a simple request. So "no antimicrobials in the previous 3 months" — which changes the recommended regimen — has to be asked about specifically, because the patient may not think of a pharmacy purchase as taking an antibiotic.

Pakistan is the third-highest antibiotic-consuming low- and middle-income country. That consumption is the engine behind the numbers above.

Substandard products are a real confounder. Antibiotics account for 16.9% of all products reported as substandard or falsified in Pakistan. A patient who has apparently failed a correct antibiotic at a correct dose may have received an inadequate product rather than harboured a resistant organism.

On sending cultures

The guideline notes the low yield argues against routine blood and sputum cultures, but also that they matter "for epidemiologic reasons, including the antibiotic susceptibility patterns used to develop treatment guidelines."

That second clause carries more weight in Pakistan than in the settings the guideline borrows from. The local susceptibility picture is thin precisely because cultures are sent inconsistently. Sending them in admitted patients is how the next version of this advice gets better numbers.

Bottom line

Confirm the infiltrate. Score the severity properly on arrival. For a previously healthy outpatient, take the guideline's amoxicillin and leave its macrolide. Do not abandon amoxicillin because penicillin looks resistant — that is a breakpoint artefact. Think twice before a respiratory fluoroquinolone, because of TB rather than pneumococcus. Ask specifically about over-the-counter antibiotic purchases. And send cultures in admitted patients, because someone has to.

Our pneumonia pathway shows the national guideline verbatim first and reconciles it against current resistance second, so you can see exactly what changed and what did not. Also in the section: urinary tract infection, type 2 diabetes and hypertension.

ReviseFCPS1 is built by doctors in Pakistan, for doctors in Pakistan. All our clinical tools and pathways are free. If you are preparing for FCPS Part 1, try it free for 7 days — 10,176 doctor-verified MCQs and 8,236 real exam recalls.